U.S. drug companies curb supplies to Canadian exporters As the political fight over drug imports into the United States intensifies, […]
U.S. drug companies curb supplies to Canadian exporters Read Post »
The next big thing is… According to the most recent MoneyTree Survey, a report put together by PricewaterhouseCoopers, Thomson Venture
Pharmaceutical Makers Turn To CRM After years of blockbuster medications that literally change the way their customers live, drugmakers are
Fog Begins to Lift with Q3 Biotech Numbers Certain market indicators for 2003�s third quarter suggest that at least some
India emerges as new drug trial hot spot Biotech entrepreneurs see Indian clinical trials � which can cut costs by
Who’s Going To Pay For Global Health? The amazingly swift global response to the SARS outbreak earlier this year demonstrated
Who’s Going To Pay For Global Health? The amazingly swift global response to the SARS outbreak earlier this year demonstrated
Seeking a Prescription for Biogenerics No U.S. laws allow for generic versions of off-patent biotech medicines. Several forces are now
Why Merck Missed the Mark S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report
Biotech: Teva’s Next Triumph? The Israeli maker of generics wants a piece of the fast-growing bio-drug market